Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen Maintenance Therapy in Neovascular AMD (LEVEL)
NCT00354445Phase 4Unknown
- Sponsor
- OSI Eyetech
- Start
- Jun 2006
- Modality
- Antisense DNA, RNA Aptamers, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of pegaptanib sodium in neovascular age-related macular degeneration (NVAMD), sponsored by OSI Eyetech. Status: unknown.
02
Drugs
pegaptanib sodium
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00354445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354445.